Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Growth Metrics

Northwest Biotherapeutics (NWBO) Gains from Investment Securities (2021 - 2022)

Northwest Biotherapeutics' Gains from Investment Securities history spans 2 years, with the latest figure at $304.6 million for Q3 2022.

Quarterly results put Gains from Investment Securities at $304.6 million for Q3 2022, changed N/A from a year ago — trailing twelve months through Sep 2022 was $304.6 million (changed N/A YoY), and the annual figure for FY2024 was $364000.0, changed.
Gains from Investment Securities for Q3 2022 was $304.6 million at Northwest Biotherapeutics, roughly flat from $304.8 million in the prior quarter.
In the past five years, Gains from Investment Securities ranged from a high of $304.8 million in Q4 2021 to a low of $304.6 million in Q3 2022.